Efficay of therapy with anti-CD20 antibody (rituximab) in a patient with autoimmune hemolytic anemia associated with rheumatoid arthritis [4];Respuesta mantenida al tratamiento con anticuerpos anti-CD20 (rituximab) en un caso de anemia hemolítica autoinmune asociada a artritis reumatoide

Medicina Clinica

Volumn 124, Issue 13, 2005, Pages 517-518

  Barquero Romero, José ^a   García Domínguez, Manuel ^a   Pérez Miranda, Manuel ^a  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; DICLOFENAC; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB;

ADULT; ALLERGIC REACTION; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; LETTER; MALE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 18844393766     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073571     Document Type: Letter

References (10)

1. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258-71.
2. Packman CH, Leddy JP. Acquired hemolytic anemias due to warn reacting autoantibodies. En: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Soligsohn U, editors. William's hematology. 6th ed. New York: McGraw Hill, 2001; p. 685.
3. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548-51.
4. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69:95-100.
5. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
6. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clinic Proc. 2003;78:1340-6.
7. Ahrens N, Kinggreen D, Seltsam A, Salama A. Treatment of refractory autoinmune haemolytic anaemia with anti cd20 (rituximab). Br J Haematol. 2001;114:244.
8. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511-3.
9. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995-7.
10. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-61.